Stryker nets $6.6bn revenue in Q2; highlights resilience following cyberattack
Stryker has reported Q2 revenues of $6.6bn, denoting a 9.4% rise year-over-year (YoY), with the company's CEO lauding its "significant progress" in recovering since its global operations were disrupted by an cyberattack in March. Following the results, Stryker is tweaking its 2026 outlook at the low end, with earnings now projected to land in the $14.95 to $15.10 per share range, up from $14.90 to $15.10 previously.
How this was made
The 30-second read
Why it matters
Q2 results show 9.4% YoY revenue growth to $6.6bn, but the medsurg and neurotechnology segment revenue of about $3.6bn missed analysts’ $3.72bn expectation. Management also adjusted 2026 outlook to the low end, with EPS projected at $14.95 to $15.10 versus $14.90 to $15.10 previously, framing the quarter as progress in recovery.
Market read
Traders can use the updated 2026 EPS range and the segment revenue miss versus LSEG expectations to reassess near-term estimates and risk premium tied to operational disruption.
What to watch
The article highlights an orthopaedic segment near $3bn with 9.2% YoY growth; if investors underweight this strength versus the medsurg and neurotechnology miss, the stock could stabilize.
Background
Stryker’s global operations were disrupted by an Iran-linked cyberattack in March, affecting internal infrastructure and its Cork, Ireland headquarters first.
Ticker impact
Stryker reported Q2 revenue of $6.6bn and guided 2026 EPS to $14.95 to $15.10 after a March cyberattack recovery.
Choppy trading risk, with downside bias if the segment miss dominates and upside if investors focus on recovery and cash flow strength.
The article provides concrete Q2 results, a specific 2026 EPS range change, and a stated segment revenue miss versus LSEG expectations, all of which can drive immediate repricing.
Market effects
Medtech investors may reprice cyber-resilience and operational continuity risk for large medtech operators, not just growth.
Limited direct regional read-through beyond Ireland-based operational disruption.
Cyber incident recovery and guidance adjustments can influence broader medtech risk appetite globally.
Counterpoint
The low-end guidance tweak may be more about conservatism after disruption, while strong Q2 growth and operating cash flow suggest the market is over-penalizing the incident.
Key entities
- companyStryker
Reported Q2 revenue of $6.6bn, adjusted 2026 EPS guidance, and discussed recovery progress after a March cyberattack.
- threat_actorHandala
Iran-linked hacktivist group that claimed responsibility for the March cyberattack via Telegram.
